IRIS
MONTIRONI, Rodolfo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.165
EU - Europa 13.861
AS - Asia 4.932
AF - Africa 179
Continente sconosciuto - Info sul continente non disponibili 52
SA - Sud America 20
OC - Oceania 8
Totale 49.217
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.129
UA - Ucraina 3.817
IE - Irlanda 2.233
TR - Turchia 1.883
SE - Svezia 1.770
DE - Germania 1.741
DK - Danimarca 1.434
IT - Italia 1.342
SG - Singapore 1.203
CN - Cina 881
KR - Corea 776
FI - Finlandia 767
GB - Regno Unito 575
CI - Costa d'Avorio 169
IN - India 131
FR - Francia 53
EU - Europa 52
BE - Belgio 51
CA - Canada 33
RU - Federazione Russa 22
BR - Brasile 15
ID - Indonesia 14
VN - Vietnam 14
JP - Giappone 13
NL - Olanda 11
CH - Svizzera 7
RO - Romania 6
AU - Australia 5
BG - Bulgaria 4
EG - Egitto 4
IL - Israele 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
ES - Italia 3
LU - Lussemburgo 3
MX - Messico 3
NZ - Nuova Zelanda 3
PL - Polonia 3
AT - Austria 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HK - Hong Kong 2
IR - Iran 2
KE - Kenya 2
LY - Libia 2
PT - Portogallo 2
SA - Arabia Saudita 2
UY - Uruguay 2
BY - Bielorussia 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 49.217
Salva come PNG Salva come JPEG
Città #
Jacksonville 3.923
Chandler 3.305
Fairfield 3.242
Dublin 2.229
Ashburn 1.914
Des Moines 1.838
Wilmington 1.762
Woodbridge 1.433
Houston 1.238
Seattle 1.195
Boardman 1.167
Cambridge 1.008
Lawrence 908
Princeton 908
San Mateo 892
New York 792
Ann Arbor 600
San Diego 419
Centro 414
Singapore 278
Milan 232
Abidjan 169
London 149
Pune 125
Beijing 124
Norwalk 93
Shanghai 92
Washington 92
Redmond 79
Guangzhou 78
Los Angeles 75
Wuhan 72
Izmir 67
Falls Church 61
Helsinki 53
Brussels 49
Marche 48
Kilburn 44
Turin 43
Jiaxing 36
Rome 34
Ancona 29
Seoul 27
Porto 26
Prescot 26
Venice 26
Wuxi 24
Yiwu 22
New Bedfont 20
Tappahannock 20
Shenzhen 18
Chiswick 17
Berlin 16
Auburn Hills 15
Hounslow 15
Acton 13
Dong Ket 13
Jinhua 13
Chicago 12
Fayetteville 12
Ottawa 12
Bologna 11
Wandsworth 11
Hanover 10
Southwark 10
Edinburgh 9
Forlì 9
Frankfurt am Main 9
Nanjing 9
Pesaro 9
Phoenix 9
Quanzhou 9
Sheffield 9
Simi Valley 9
Strasbourg 9
Essen 8
Redwood City 8
Fuzhou 7
Montréal 7
Palermo 7
Torre Del Greco 7
Islington 6
Menlo Park 6
Saint Petersburg 6
Stockholm 6
São Paulo 6
Amsterdam 5
Heze 5
Mountain View 5
Ostra Vetere 5
Tolentino 5
Torino 5
Toronto 5
Zurich 5
Appignano 4
Buffalo 4
Canosa di Puglia 4
Civitanova Marche 4
Forest City 4
Foshan 4
Totale 31.926
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 150
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 127
Role of DNA analysis and mutation of P53 gene in small dimension renal carcinomas. Biological significance and long-term follow-up 123
Immunotherapy in genitourinary cancers: Where are we going? 116
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 115
Green fluorescent protein as indicator of non-viral transient transfection efficiency in endometrial and testicular biopsies 109
Atypical foci, suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy") 106
Chromosomal Abnormalities in Macroscopically Normal Urothelium in Patiens with Bladder pT1 and pT2a Urothelial Carcinoma: a Fluorescence in situ hybridisation Study and Correlation with Histologic Features. 106
Clinical performance and utility of a NNMT-based urine test for bladder cancer 104
Microbiome and cancers, with focus on genitourinary tumors 103
Computer assisted discrimination of glioblastomas 103
Metabolic phenotype of bladder cancer 102
Activity and expression of nitric oxide synthase in rat bladder after sacral neuromodulation 100
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 100
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 99
Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma 98
Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study. 98
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 97
Ciliary neurotrophic factor (CNTF) and its receptor (CNTFRα) signal through MAPK/ERK pathway in human prostate tissues: a morphological and biomolecular study 97
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 95
Molecular diagnostics in uro-oncology 95
HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected andreogen-dependent and androgen-independent cancer. 94
Secondary neoplasms of the urinary system and male genital organs. 94
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 94
Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. 92
From undergraduate medical school student to visible pathologist 92
Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis 91
Cardiac myxoma with glandular elements metastatic to the brain 12 years after the removal of the original tumor 91
Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. 90
Cytometric Evidence That Cervical Intraepithelial Neoplasia-i and Neoplasia-ii Are Dysplasias Rather Than True Neoplasias - An Image-analysis Study of Factors Involved In the Progression of Cervical Lesions 90
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 90
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 90
Metabolic Alterations in Renal and Prostate Cancer 89
Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1) 88
Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. 87
alpha-methylacyl-CoA racemase (P504S)/34 beta E12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy 87
Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading 87
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling 87
Quantitative-analysis of Prostatic Intraepithelial Neoplasia On Tissue-sections. 87
Is There a Role for Immunotherapy in Prostate Cancer? 87
Computer assisted analysis of medulloblastoma: a cytological study 86
Succinate dehydrogenase-deficient renal cell carcinoma: Detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma 86
The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. 85
Morphological diagnosis of urothelial neoplasms. 85
TGFb1 immunohistochemistry in goiter; comparison of patients with recurrence or non recurrence 84
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. 84
Cognitive zonal fusion biopsy of the prostate: Original technique between target and saturation. 84
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 84
Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. 83
Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis 83
"Pathological" reflection on European urology: extended, saturation, and systematic prostate biopsies. 83
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 83
Pd-l1 inhibitors for the treatment of prostate cancer 83
Expert system support using a Bayesian belief network for the classification of endometrial hyperplasia 82
Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? 82
Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network. 82
Urothelial papillary lesions. Development of a Bayesian Belief Network for diagnosis and grading 82
Do DNA methylation and histone acetylation play a role in clear cell renal carcinoma? Analysis of radical nephrectomy specimens in a long-term follow-up. 82
Joint appraisal of the radical prostatectomy specimen by the urologist and the uropathologist: together, we can do it better 82
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 82
2004 WHO classification of the renal tumors of the adults. 82
Perivascular epithelioid cell tumor (PEC-ome) of the prostate: ultrasound feature in case report 82
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 82
Statistical histometry of the basal cell secretory cell bilayer in prostatic intraepithelial neoplasia. 81
Editorial comment on: validation of the contemporary epstein criteria for insignificant prostate cancer in European men. 81
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 81
Pathology in prostate research: Optimizing tissue quality 80
Extent of cancer of less than 50% in any prostate needle biopsy core: how many millimeters are there? 80
Impact of prostate cancer multifocality on its biology and treatment. 79
HtrA1 in human urothelial bladder cancer: a secreted protein and a potential novel biomarker. 79
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 79
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 79
Predicting future cancer burden in the United States by artificial neural networks 79
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 79
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 79
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 79
Diagnostic Criteria for Ductal Adenocarcinoma of the Prostate.Interobserver Variability among 20 Expert Uropathologists. 79
Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma 78
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 78
The human microbiota and prostate cancer: Friend or foe? 78
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 78
Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. 77
[Gleason's grading of prostatic cancer: a current perspective]. 77
Chromatin texture signatures in nuclei from prostate lesions 77
D2-40 immunoreactivity in penile squamous cell carcinoma: a marker of aggressiveness 77
Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. 77
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 77
Screening for prostatic cancer and its evolution within Britain 76
Aneuploidy and nuclear features of prostatic intraepithelial neoplasia (PIN). 76
2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections 76
Genitourinary cancers: molecular determinants for personalized therapies 76
Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors 75
Pathology of prostate cancer and focal therapy ('male lumpectomy'). 75
Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique 75
Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: Progress pathology report of the Italian PROSIT study 75
Evaluation of prognostic factors in radical prostatectomy specimens with cancer 75
Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. 75
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 75
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 75
Epigenetic modifications and modulators in prostate cancer 75
Totale 8.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 273.403
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 273.403
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.418 20 3 790 14 778 21 786 8 780 32 78 1.108
2020/202112.955 612 1.238 1.572 269 1.517 1.477 1.215 933 1.163 1.130 1.275 554
2021/20226.642 620 1.542 134 320 93 552 203 432 475 538 386 1.347
2022/202311.128 1.119 780 604 975 804 2.588 11 659 2.830 51 421 286
2023/20246.133 1.239 165 345 998 1.049 1.158 112 111 20 109 56 771
2024/2025748 748 0 0 0 0 0 0 0 0 0 0 0
Totale 49.918